JNJ-9892
/ J&J
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 30, 2026
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
(clinicaltrials.gov)
- P1 | N=155 | Recruiting | Sponsor: Janssen Research & Development, LLC | N=63 ➔ 155
Enrollment change • First-in-human • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
April 04, 2026
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
(clinicaltrials.gov)
- P1 | N=155 | Recruiting | Sponsor: Janssen Research & Development, LLC | N=100 ➔ 155
Enrollment change • First-in-human • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
April 08, 2025
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
(clinicaltrials.gov)
- P1 | N=100 | Recruiting | Sponsor: Janssen Research & Development, LLC | Not yet recruiting ➔ Recruiting
Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
1 to 3
Of
3
Go to page
1